# Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

> **NCT00447330** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 60 (actual)

## Conditions studied

- Esophageal Neoplasms
- Stomach Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT00447330
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2014-01
- **Final completion:** 2014-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-02-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447330, "Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT00447330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*